An Independent Clinical Study Shows Association between ChemoFx® Results and Recurrence Free Survival in Cervical Cancer by longitudeadmin | Apr 30, 2013 | Portfolio News
Esperion Therapeutics Completes $33 Million Preferred Financing to Advance Its Novel Oral LDL-C Lowering Therapy to Later Stage Clinical Trials by longitudeadmin | Apr 26, 2013 | Portfolio News
Study takes ‘cool’ approach to reducing heart attack damage by longitudeadmin | Apr 25, 2013 | Portfolio News
Amarin Announces FDA Acceptance of Supplemental New Drug Application (sNDA) for Vascepa(R) for the Treatment of Patients With High Triglycerides (>200 mg/dL and <500 mg/dL) With Mixed Dyslipidemia by longitudeadmin | Apr 23, 2013 | Portfolio News
Civitas Therapeutics Announces Positive Phase 2 Clinical Results for CVT-301, an Inhaled L-dopa for Parkinson’s Disease by longitudeadmin | Apr 19, 2013 | Portfolio News
